Fortress Biotech partner gets rights to Lilly's Qbrexza

1 April 2021

Fortress Biotech (Nasdaq: FBIO) partner company Journey Medical today announced that it has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the USA from Dermira, a wholly-owned subsidiary of Eli Lilly (NYSE: LLY).

The transaction, financial terms of which were not disclosed, is expected to close early in the second quarter of this year. Qbrexza generated $24 million in net sales in the USA in 2020.

Qbrexza was approved by the US Food and Drug Administration in 2018, and is the only topical product for treatment of primary axillary hyperhidrosis in adult and pediatric populations (ages nine-years and older) and is self-administered by patients, cleared by the FDA. Additionally, Qbrexza is noted as a first-line treatment therapy for primary axillary hyperhidrosis by the International Hyperhidrosis Society (IHHS). Hyperhidrosis is a condition of sweating beyond what is physiologically required for normal thermal regulation and affects an estimated 4.8% of the US population, or around 15 million people.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK